Effect of Ramipril in Reducing Sudden Deaths and Nonfatal Cardiac Arrests in High-Risk Individuals Without Heart Failure or Left Ventricular Dysfunction (original) (raw)

Abstract

Background-ACE inhibitor therapy reduces the risk of cardiovascular death, myocardial infarction, stroke, hospitalization for heart failure, and need for revascularization in high-risk patients with clinical heart failure, overt left ventricular systolic dysfunction, or vascular disease. In patients with clinical heart failure or overt left ventricular systolic dysfunction, ACE inhibitor therapy also reduces the risk of sudden or arrhythmia-related cardiac death. The objective of this study was to assess the effect of the ACE inhibitor ramipril on sudden unexpected death or resuscitated cardiac arrest among the 9297 individuals without clinical heart failure or overt left ventricular dysfunction enrolled in the Heart Outcomes Prevention Evaluation (HOPE) trial. Methods and Results-During the median follow-up of 4.5 years, the composite outcome of unexpected death, documented arrhythmic death, or resuscitated cardiac arrest was reduced by 21% in patients randomized to ramipril therapy compared with those randomized to placebo. There were 155 (3.3%) composite outcome events in patients randomized to ramipril therapy compared with 195 (4.2%) such events in patients randomized to placebo (RR 0.79, 95% CI 0.64 to 0.98, Pϭ0.028). There were trends toward reductions in fatal primary outcome events (unexpected death or documented arrhythmic death; RR 0.81, 95% CI 0.64 to 1.02, Pϭ0.072) and in nonfatal primary outcome events (resuscitated cardiac arrest; RR 0.65, 95% CI 0.38 to 1.13, Pϭ0.127) in the ramipril treatment group. Conclusions-Ramipril reduces the risk of fatal and nonfatal serious arrhythmic events in high-risk patients without clinical heart failure or overt left ventricular systolic dysfunction. (Circulation. 2004;110:1413-1417.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (29)

  1. Lonn E, Yusuf S, Jha P, et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation. 1994; 90:2056 -2069.
  2. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhib- itors on mortality and morbidity in patients with heart failure. JAMA. 1995;273:1450 -1456.
  3. Pfeffer MA, Braunwald E, Moye L, et al, on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival And Ventricular Enlargement trial. N Engl J Med. 1992;327: 669 -677.
  4. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342: 821-828.
  5. Kober L, Torp-Pedersen C, Carlsen JE, et al, for the Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin- converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1995;333: 1670 -1676.
  6. Ambrosioni E, Borghi C, Magnani B, for the Survival of Myocardial Infarction Long-term Evaluation (SMILE) Study Investigators. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med. 1995; 332:80 -85.
  7. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
  8. The SOLVD Investigators. Effect of enalapril on mortality and the devel- opment of heart failure in asymptomatic patients with reduced left ven- tricular ejection fractions [published erratum appears in N Engl J Med 1992;327:1768].
  9. N Engl J Med. 1992;327:685-691.
  10. Domanski MJ, Exner DV, Borkowf CB, et al. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients fol- lowing acute myocardial infarction: a meta-analysis of randomized clinical trials. J Am Coll Cardiol. 1999;33:598 -604.
  11. The Heart Outcomes Prevention Evaluation Investigators. Effects of an angiotensin converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-153.
  12. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303-310.
  13. HOPE Study Investigators. The HOPE (Heart Outcomes Prevention Eval- uation) Study: the design of a large, simple, randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Can J Cardiol. 1996;12: 127-137.
  14. Cox DR. Regression models and lifetables. J R Stat Soc (B). 1972;34: 187-220.
  15. Kaplan EL, Meier P. Nonparametric estimation from incomplete obser- vations. J Am Stat Assoc. 1958;53:457-481.
  16. The Heart Outcomes Prevention Evaluation Investigators. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med. 2000;342:154 -160.
  17. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet. 1995;345:669 -685.
  18. Swedberg K, Held P, Kjekshus J, et al, on behalf of the CONSENSUS II Study Group. Effects of early administration of enalapril on mortality in patients with acute myocardial infarction: results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med. 1992;327:678 -684.
  19. Hattori Y, Atsushi S, Hiroaki F, et al. Effects of cilazapril on ventricular arrhythmia in patients with congestive heart failure. Clin Ther. 1997;19: 481-486.
  20. Benedict CR, Weiner DH, Johnstone DE, et al, for the SOLVD Investi- gators. Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: results of the Studies Of Left Ventricular Dysfunction (SOLVD) Registry. J Am Coll Cardiol. 1993;22(suppl A):146A-153A.
  21. Benedict CR, Johnstone DE, Weiner DH, et al, for the SOLVD Investi- gators. Relation of neurohormonal activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. J Am Coll Cardiol. 1994;23:1410 -1420.
  22. Francis GS, Benedict C, Johnstone DE, et al, for the SOLVD Investi- gators. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Cir- culation. 1990;82:1724 -1729.
  23. Benedict CR, Shelton B, Johnstone DE, et al, for the SOLVD Investi- gators. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. Circulation. 1996;94: 690 -697.
  24. Swedberg K, Eneroth P, Kjekshus J, et al, for the CONSENSUS Trial Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relationship to mortality. Circulation. 1990;82:1730 -1736.
  25. Benedict CR, Francis GS, Shelton B, et al, for the SOLVD Investigators. Effect of long-term enalapril therapy on neurohormones in patients with left ventricular dysfunction. Am J Cardiol. 1995;75:1151-1157.
  26. Van Gilst VM, deGraeff PA, Wesseling H, et al. Reduction of reperfusion arrhythmias in the ischemic isolated rat heart by angiotensin converting enzyme inhibitors: a comparison of captopril, enalapril and HOE498. J Cardiovasc Pharmacol. 1986;8:722-728.
  27. Linz W, Martorana PA, Scholkens BA. Local inhibition of bradykinin degradation in ischemic hearts. J Cardiovasc Pharmacol. 1990;15(suppl 6):S99 -S109.
  28. Kingma JH, deGraeff PA, Van Gilst WH, et al. Effects of intravenous captopril on inducible sustained ventricular tachycardia one week after experimental infarction in anaesthetized pig. Postgrad Med J. 1986; 62(suppl I):159 -163.
  29. The European trial on Reduction Of Cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA Study). Lancet. 2003;362:782-788.